Sign In
CORT.US
id: 585

Corcept Therapeutics (CORT) $14M Securities Settlement

Late claims are being considered for compensation, subject to approval.
N.D. California
Court
3:19-CV-01372
Case number
08/02/2017
Class period Start
01/31/2019
Class period End
05/13/2024
Claim deadline

Corcept Therapeutics (CORT) agreed to settle $14 million with investors to end a securities class action lawsuit over concealing that it improperly paid doctors to promote its drug Korlym and inflated its revenue and sales using illicit sales practices through a related party.

Case Status
Accepting Late Claims
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.06
Filing date
03/14/2019
Lead Plaintiff Deadline
05/13/2019
Plaintiffs
Ferraro Family Foundation
Attorneys
Levi & Korsinsky, LLP (San Francisco, CA)
Defendants
Joseph K. Belanoff, Charles Robb, Sean Maduck
Judge
Hon. Lucy H. Koh
Administrator
A.B. Data Ltd
Settlement agreement date
2023-04-11
Court hearing date
06/06/2024
Exclusion deadline
05/13/2024
Objection deadline
05/13/2024
Trades matching type
FIFO
+$14,000,000
Cash Settlement Amount

Frequently Asked Questions

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It o...

    Ticker
    CORT.US
    ISIN
    US2183521028
    CIK
    1088856
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    149 Commonwealth Drive, Menlo Park, CA, United States, 94025